Literature DB >> 9088068

Parathyroid function and bone metabolic markers in primary and secondary hyperparathyroidism.

Y Tanaka1, H Funahashi, T Imai, Y Tominaga, H Takagi.   

Abstract

Remarkable changes of parathyroid function immediately after parathyroidectomy were evaluated in primary (PHPT) and secondary (RHPT) hyperparathyroidism. Bone metabolism was also evaluated by new specific markers of bone formation and resorption. A rapid decline into the undetectable range, and a rapid recovery of serum bioactive parathyroid hormone (PTH) concentrations were observed after parathyroidectomy in PHPT. Since the function of the remnant parathyroid glands was not clear, we investigated the transcription of PTH mRNA. Despite the suppression of PTH secretion in the remnant parathyroid glands, no significant difference was found in the amount of PTH mRNA present in an adenoma as compared to a remnant gland when evaluated by cytoplasmic dot hybridization and in situ hybridization. Although measurement of serum PTH concentration by assays of inactive fragment was available for the longterm follow-up of PTH function in RHPT, parathyroid function should be evaluated by biologically active intact PTH immediately after operation. The PTH gradient also was successfully evaluated by the measurement of intact PTH. A discrepancy was observed between bone resorption evaluated by type I collagen cross-linked N-telopeptide as compared to bone formation evaluated by osteocalcin immediately after operation. This discrepancy will improve and bone mineral density will increase in the first 6 months after parathyroidectomy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088068     DOI: 10.1002/(sici)1098-2388(199703/04)13:2<125::aid-ssu8>3.0.co;2-b

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  2 in total

1.  The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy.

Authors:  S Alonso; E Ferrero; M Donat; G Martínez; C Vargas; M Hidalgo; E Moreno
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

2.  Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

Authors:  Claudio Marcocci; Philippe Chanson; Dolores Shoback; John Bilezikian; Laureano Fernandez-Cruz; Jacques Orgiazzi; Christoph Henzen; Sunfa Cheng; Lulu Ren Sterling; John Lu; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.